[{"id":"976f7440-4689-49dd-a48e-afbffc7bdabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660929","created_at":"2021-01-19T20:42:33.281Z","updated_at":"2024-07-02T16:35:10.054Z","phase":"Phase 1","brief_title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","source_id_and_acronym":"NCT04660929","lead_sponsor":"Carisma Therapeutics Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CT-0508"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-11"}]